The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy
Open accessAbstract
Graves’ orbitopathy (GO) is the main extrathyroidal manifestation of Graves’ disease (GD). Choice of treatment should be based on the assessment of clinical activity and severity of GO. Early referral to specialized centers is fundamental for most patients with GO. Risk factors include smoking, thyroid dysfunction, high serum level of thyrotropin receptor antibodies, radioactive iodine (RAI) treatment, and hypercholesterolemia. In mild and active GO, control of risk factors, local treatments, and selenium (selenium-deficient areas) are usually sufficient; if RAI treatment is selected to manage GD, low-dose oral prednisone prophylaxis is needed, especially if risk factors coexist. For both active moderate-to-severe and sight-threatening GO, antithyroid drugs are preferred when managing Graves’ hyperthyroidism. In moderate-to-severe and active GO i.v. glucocorticoids are more effective and better tolerated than oral glucocorticoids. Based on current evidence and efficacy/safety profile, costs and reimbursement, drug availability, long-term effectiveness, and patient choice after extensive counseling, a combination of i.v. methylprednisolone and mycophenolate sodium is recommended as first-line treatment. A cumulative dose of 4.5 g of i.v. methylprednisolone in 12 weekly infusions is the optimal regimen. Alternatively, higher cumulative doses not exceeding 8 g can be used as monotherapy in most severe cases and constant/inconstant diplopia. Second-line treatments for moderate-to-severe and active GO include (a) the second course of i.v. methylprednisolone (7.5 g) subsequent to careful ophthalmic and biochemical evaluation, (b) oral prednisone/prednisolone combined with either cyclosporine or azathioprine; (c) orbital radiotherapy combined with oral or i.v. glucocorticoids, (d) teprotumumab; (e) rituximab and (f) tocilizumab. Sight-threatening GO is treated with several high single doses of i.v. methylprednisolone per week and, if unresponsive, with urgent orbital decompression. Rehabilitative surgery (orbital decompression, squint, and eyelid surgery) is indicated for inactive residual GO manifestations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne, J. A. C., Murthy, S., Diaz, J. V., Slutsky, A. S., Villar, J., Angus, D. C., Annane, D., Azevedo, L. C. P., Berwanger, O., et al. (2020) · JAMA · doi:10.1001/jama.2020.17023 · Cited by 2,257
Relation between Therapy for Hyperthyroidism and the Course of Graves' Ophthalmopathy
Bartalena, L., Marcocci, C., Bogazzi, F., Manetti, L., Tanda, M. L., Dell'Unto, E., Bruno-Bossio, G., Nardi, M., Bartolomei, M. P., Lepri, A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380201 · Cited by 715
Self-citationOccurrence of Ophthalmopathy after Treatment for Graves' Hyperthyroidism
Tallstedt, L., Lundell, G., Tørring, O., Wallin, G., Ljunggren, J.-G., Blomgren, H., & Taube, A. (1992) · New England Journal of Medicine · doi:10.1056/nejm199206253262603 · Cited by 521
Laurberg, P., Wallin, G., Tallstedt, L., Abraham-Nordling, M., Lundell, G., & Tørring, O. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0450 · Cited by 428
Wiersinga, W. M. (2013) · Clinical Endocrinology · doi:10.1111/cen.12222 · Cited by 389
Self-citationEffect of Abnormal Thyroid Function on the Severity of Graves' Ophthalmopathy
Prummel, M. F. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.1990.00390170124027 · Cited by 238
Pfeilschifter, J., & Ziegler, R. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.8220832.x · Cited by 227 · cited 1×
“…have more severe GO (3); development or progression of GO after radioactive iodine (RAI) treatment is more frequent in smokers (47, 48); smokers have a delayed or worse outcome of immunosuppressive treatments (47, 49, 50); smoking cessation is possibly associated with a better outcome of GO (51).”
Perros, P., Kendall-Taylor, P., Neoh, C., Frewin, S., & Dickinson, J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0507 · Cited by 156
Cited by
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis
Wiersinga, W. M., Poppe, K. G., & Effraimidis, G. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00005-0 · Cited by 254
Self-citationTargeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress
Gjølberg, T. T., Mester, S., Calamera, G., Telstad, J. S., Sandlie, I., & Andersen, J. T. (2025) · BioDrugs · doi:10.1007/s40259-025-00708-2 · Cited by 20
Wanas, A. M., Giacuzzo, C., Ghazi-Nouri, S., & Tan, L. T. (2025) · Orbit · doi:10.1080/01676830.2023.2296553 · Cited by 6
Metadata
- Authors
- Bartalena, L., Kahaly, G. J., Baldeschi, L., Dayan, C. M., Eckstein, A., Marcocci, C., Marinò, M., Vaidya, B., Wiersinga, W. M., _, _., _, _., Ayvaz, G., Konuk, O., Ciric, J., Beleslin, B., Boschi, A., Cristina Burlacu, M., Morris, D., Le Moli, R., Marino, A., McKee, J., Zammit, N., Führer, D., Pereni, I., Schittkowski, M., Raddatz, D., Lee, V., Meeran, K., Abeillon, J., Soui Thcong, T., Ponto, K., Muller, I., Currò, N., Hintschich, C., Gärtner, R., Pearce, S., Clarke, L., Brix, T., Bechtold, D., Rudovfsky, G., Fichter, N., Du Pasquier, L., Meney, J., Menconi, F., Lanzolla, G., Sundar, G., Peiling Yung, S., Boboridis, K., Anagnostis, P., Pérez Lopez, M., Javier Sanchez, C., Laura Tanda, M., Donati, S., Papp, A., Li, S., Jablonska, A., Miskiewicz, P., Juri Mandic, J., & Baretic, M.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-10-01
- Volume
- 185
- Issue
- 4
- Pages
- G43-G67
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W3186410608
- Cited by
- 1,054
- References
- 8
- FWCI
- 80.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. https://app.cochat.ai/papers/10.1530/eje-21-0479
- The paper
- Bartalena, L., Kahaly, G. J., Baldeschi, L., Dayan, C. M., Eckstein, A., Marcocci, C., Marinò, M., Vaidya, B., Wiersinga, W. M., _, _., _, _., Ayvaz, G., Konuk, O., Ciric, J., Beleslin, B., Boschi, A., Cristina Burlacu, M., Morris, D., Le Moli, R., . . . Baretic, M. (2021). The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. European Journal of Endocrinology. https://doi.org/10.1530/eje-21-0479
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.